我国新冠疫苗已接种6万人

Trials of China's vaccines
我国新冠疫苗已接种6万人

China currently has 13 vaccine candidates in clinical trials, of which three inactivated vaccines and one adenovirus vector vaccine are in phase three trials, said Tian Baoguo, deputy head of the Department of Science and Technology for Social Development of the Ministry of Science and Technology.
科技部社会发展科技司副司长田保国介绍，目前我国已有13个疫苗进入临床试验阶段。其中，三款灭活疫苗和一款腺病毒载体疫苗进入三期临床试验。

And about 60,000 volunteers have been inoculated with the four vaccine candidates.
截至目前，共计约6万名受试者接种，未收到严重不良反应的报告。

No severe adverse reaction has been reported among them, and preliminary results show that these vaccines are generally safe and only have minor side effects such as pain and bruising at the injection site, as well as temporary low-grade fever.
初步结果显示，这些疫苗总体上是安全的，发生的不良反应基本为轻度不良反应，比如接种部位局部疼痛、红肿，以及一过性的低烧、发热等。

Zheng Zhongwei, head of China's COVID-19 vaccine development task force, said the nation's annual COVID-19 vaccine production capacity could reach 610 million doses this year and will expand further next year.
科研攻关组疫苗研发专班工作组组长郑忠伟介绍，预计今年年底我国新冠疫苗的年产能可达到6.1亿剂，明年产能会在此基础上有效扩大。